David Dunn
David Dunn, B.Sc. has served as Chairman of KineMatik's Scientific Advisory Board since April 2007. Mr. Dunn has over thirty years of diverse experience in the diagnostics industry with management responsibilities at the Vice Presidential level in Clinical Laboratory testing; Research & Development; Quality Control; Quality Assurance; FDA & ISO Quality Systems Regulatory compliance; Corporate Regulatory compliance for DEA, EPA, OSHA, NRC and USDA; FDA product clearances and approvals including 510(k)s, INDs, PMAs and BLAs; International product registrations including CE Marks, Canadian registrations, Australian registrations, Brazilian registrations and Japanese registrations; Clinical Affairs; Medical Services; Customer Services; Instrument Repair Services; and Manufacturing. David Dunn started his career at BioDynamics, then Boehringer Mannheim. He has spent the last 13 years at Gen-Probe and Celera Diagnostics, companies focused on developing and marketing newly discovered genetic markers and amplified technology businesses. He was directly responsible for FDA approval of the first amplified nucleic acid test (NAT) for Tuberculosis as well as the first FDA approved NAT blood screening assay for HIV and HCV. Mr. Dunn received his Bachelor’s degree from Purdue University in Biology and Chemistry and is now serving as an individual consultant to the diagnostics industry.
Dr. Frank McCormick
Director of the University of California San Francisco (UCSF) Comprehensive Cancer Center and Cancer Research Institute, a multidisciplinary research and clinical care organization that is one of the largest matrix cancer centers in the Western United States. A native of Cambridge, England, McCormick received his B.Sc. in biochemistry from the University of Birmingham (1972) and his Ph.D. in biochemistry from the University of Cambridge (1975). Postdoctoral fellowships were held in the U.S. at the State University of New York at Stony Brook and in London at the Imperial Cancer Research Fund. He has been a Fellow of the Royal Society since 1996. Prior to joining the UCSF faculty, Dr. McCormick pursued cancer-related work with several Bay Area biotechnology firms, including positions with Cetus Corporation (Director of Molecular Biology, 1981-90; Vice President of Research, 1990-91) and Chiron Corporation, where he was Vice President of Research from 1991-92. In 1992 he founded Onyx Pharmaceuticals and served as its Chief Scientific Officer until 1996. In addition to his position as director of the UCSF Cancer Center, Frank McCormick holds the David A. Wood Chair of Tumor Biology and Cancer Research in UCSF's Department of Microbiology and Immunology. Dr. McCormick is the author of more than 200 scientific publications.
Brian Karlak
Brian Karlak has been developing high-end cheminformatics and bioinformatics applications for the past fifteen years at a variety of cutting-edge biotech companies, including Syrrx, Celera, and Perlegen Sciences. At Perlegen, Brian was responsible for the development and integration of their LIMS, data processing pipeline, and data visualization systems. At other companies, he has led development of an enterprise-wide tracking and monitoring system for high-throughput crystallography; an HMM-based system used to perform the first whole-genome functional analysis of the human genome; and a system for managing integrating the results from multiple bioinformatics analyses. Currently, Brian is helping build the world's most extensive open-data, open-source database at Metaweb Technologies.
|
